Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment

Abstract excerpt

Rheumatoid arthritis (RA) affects around 1.2% of the adult population. RA is one of the main reasons for work disability and premature retirement, thus substantially increasing social and economic burden. Biological disease-modifying antirheumatic drugs (bDMARDs) were shown to be an effective therapy especially in those rheumatoid arthritis (RA) patients, who did not adequately respond to conventional synthetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biosimilars and Bioanalytical Methods
• Share to Chronic Lymphocytic Leukemia Research
• Share to Rheumatoid Arthritis Research and Therapies